Curanex Pharmaceuticals (NASDAQ:CURX) Shares Down 4.3% – Here’s What Happened

Curanex Pharmaceuticals Inc (NASDAQ:CURX) dropped 4.3% during trading on Friday. The company traded as low as $4.61 and last traded at $4.62. Approximately 10,675 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 23,847 shares. The stock had previously closed at $4.83.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Curanex Pharmaceuticals presently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Stock Down 4.3%

The company has a market capitalization of $7.25 million, a PE ratio of -0.59 and a beta of -2.88. The firm has a 50-day moving average of $4.65 and a two-hundred day moving average of $5.80.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.